ENDRA Life Sciences Inc. (NDRA) stock
Close on Nov 18, 2026Market cap $6.05MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $6.05M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.96
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$5.92M
- EPS, diluted
- -$5.98
- Free cash flow
- -$5.20M
- Book value per share
- $2.55
- Diluted shares
- 2M
Trading
- Previous close
- $3.92
- Open
- $3.97
- Day's range
- $3.52 – $4.05
- Volume
- 14,081
- Average volume (20 days)
- 8,592
- 52-week range
- $2.96 – $6.80
- RSI (14 days)
- 32.3
- Volatility (1 year)
- 102.9%
- Relative volume
- 0.52×
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 18, 2026. The S&P 500 is measured by the SPY fund.
| Period | NDRA | S&P 500 | Difference | NDRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.9% | -4.3% | −10.5 pts | ||
| 3 months | -10.5% | -4.6% | −5.9 pts | ||
| Year to date | -10.9% | +7.9% | −18.8 pts | ||
| 1 year | -39.7% | +11.8% | −51.5 pts | ||
| 3 years | -99.8% | +68.0% | −167.7 pts | -86.7% | +18.9% |
| 5 years | -100.0% | +66.2% | −166.2 pts | -83.9% | +10.7% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ENDRA Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Update
About ENDRA Life Sciences
Electromedical & Electrotherapeutic Apparatus
ENDRA Life Sciences Inc. is a medical technology company developing Thermo-Acoustic Enhanced Ultrasound (TAEUS), a non-invasive platform designed to evaluate tissue composition and assess liver fat at the point of care. The company focuses primarily on liver applications to detect and monitor metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Its initial liver product operates alongside conventional ultrasound systems to measure liver fat without requiring large capital equipment investments. The company targets pharmaceutical firms and clinical research organizations conducting metabolic trials, concierge primary care networks, bariatric and metabolic clinics, and broader primary and internal medicine practices.
Company profile, executives and historyENDRA Life Sciences stock: common questions
What is ENDRA Life Sciences's stock price?
NDRA closed at $4.04 on Nov 18, 2026, up 2.93% on the day. Over the past 52 weeks it traded between $2.96 and $6.80.
What is ENDRA Life Sciences's market cap?
ENDRA Life Sciences was worth $6.05M at the close on Nov 18, 2026: the share price times the diluted shares outstanding.
What is NDRA's P/E ratio?
ENDRA Life Sciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$5.98), so it has no meaningful P/E ratio.
Does ENDRA Life Sciences pay a dividend?
No. ENDRA Life Sciences has not paid a cash dividend over the last twelve months.
How has NDRA stock performed over the past year?
Including dividends, NDRA returned -39.7% over the past year, against +11.8% for the S&P 500.
How many NDRA shares are sold short?
0M shares were sold short at the latest FINRA report, 2.98% of the float, or 2.0 days of average trading volume.
Who are ENDRA Life Sciences's competitors?
Companies most similar to ENDRA Life Sciences by business, industry and size include QTI, FOCL, ENDV, TMDX, HYPR.
See a number that looks wrong?